Clinical Trial Continuity and the Impact of COVID-19

Here’s a second chance to catch the fascinating keynote panel discussion lead by Josh Rose, VP GM Virtual Trial Solutions Business, IQVIA and joined by Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen.
See how you can prepare for a post-Covid world and ensure your clinical trials are more patient-centric than ever before.
You can join IQVIA at our next Online Clinical Operations Strategy Meeting on November 16.

Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago
Latest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease
Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...
2 years agoLatest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease
Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...
2 years ago
Using Translational Research to Bridge the Gap Between Preclinical and Clinical Research
The disparity between animal models and clinical efficacy is compromising the safety and efficacy of therapeutic drugs. Translational research is building the bridge between preclinical studies and therapeutic treatment. Genomic techniques and non-traditional animal models are examples of translational approaches...
2 years agoUsing Translational Research to Bridge the Gap Between Preclinical and Clinical Research
The disparity between animal models and clinical efficacy is compromising the safety and efficacy of therapeutic drugs. Translational research is building the bridge between preclinical studies and therapeutic treatment. Genomic techniques and non-traditional animal models are examples of translational approaches...
2 years ago